Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Gentian Diagnostics

Less than 1K followers

GENT

Oslo Børs

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus

Gentian Diagnostics is a medical diagnostics company that develops and manufactures in vitro diagnostic reagents for high-throughput analyzers. Gentian's expertise and focus lies in homogeneous immunoassays, specifically infections, inflammation, renal failure and congestive heart failure. The company's headquarters and production facilities are located in Moss, Norway, and serves the global human and veterinary diagnostics market through sales and representative offices in a number of key countries.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
5.5.
2026

General meeting '26

6.5.
2026

Interim report Q1'26

6.5.
2026

Annual dividend

All
Press releases
ShowingAll content types
Regulatory press release2/19/2026, 9:21 AM

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release2/13/2026, 8:26 AM

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release2/12/2026, 3:09 PM

GENT: Mandatory notification of trade

Gentian Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release2/12/2026, 8:49 AM

Gentian Diagnostics: Key information relating to the proposed cash dividend

Gentian Diagnostics
Regulatory press release2/11/2026, 7:23 AM

GENT: Update on the development of the NT-proBNP assay

Gentian Diagnostics
Regulatory press release2/11/2026, 7:19 AM

Gentian Diagnostics: Fourth quarter 2025 report

Gentian Diagnostics
Regulatory press release2/4/2026, 7:22 AM

Gentian Diagnostics: Invitation to presentation of fourth quarter results

Gentian Diagnostics
Regulatory press release1/28/2026, 1:38 PM

GENT: Gentian Diagnostics invites to NT-proBNP educational webinar

Gentian Diagnostics
Regulatory press release1/7/2026, 9:04 AM

GENT: Gentian Diagnostics announces exclusive partnership for the development of a novel diagnostic assay with a leading global IVD company

Gentian Diagnostics
Regulatory press release12/18/2025, 8:06 AM

Gentian Diagnostics: Update on NT-proBNP

Gentian Diagnostics
Regulatory press release11/25/2025, 7:10 AM

GENT: Gentian Diagnostics presents at the DNB Nordic Healthcare Conference

Gentian Diagnostics
Regulatory press release11/11/2025, 10:32 AM

GENT: Financial calendar

Gentian Diagnostics
Regulatory press release10/28/2025, 7:41 AM

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release10/23/2025, 8:15 AM

Gentian Diagnostics: Study Confirms the Value of Calprotectin in Early Detection of Neonatal Infections and Sepsis

Gentian Diagnostics
Regulatory press release10/23/2025, 6:00 AM

Gentian Diagnostics: Third quarter 2025 report

Gentian Diagnostics
Regulatory press release10/16/2025, 7:55 AM

Gentian Diagnostics: Invitation to presentation of third quarter results

Gentian Diagnostics
Regulatory press release9/16/2025, 6:11 AM

GENT: Gentian Diagnostics presents at the Pareto Securities Healthcare conference

Gentian Diagnostics
Regulatory press release7/10/2025, 6:00 AM

Gentian Diagnostics: Second quarter 2025 report

Gentian Diagnostics
Regulatory press release7/3/2025, 11:22 AM

Gentian Diagnostics: Invitation to presentation of second quarter results

Gentian Diagnostics
Regulatory press release5/23/2025, 9:39 AM

GENT: Disclosure of shareholding

Gentian Diagnostics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.